On 12 February 2025, UCB announced that two-year data from the BE HEARD trials for Bimzelx® (bimekizumab) demonstrated sustained disease control in patients with moderate to severe hidradenitis suppurativa (HS).
The data revealed that after two years of treatment with bimekizumab, 53.1% of patients achieved mild disease status, compared to 0.0% at baseline. Additionally, 83.4% of patients remained flare-free, and 86.9% of those who responded to treatment at 48 weeks maintained their response.
UCB launched its high dose presentation of Bimzelx® in the US in January 2025. Bimzelx® has received several FDA approvals for new indications in recent months, including for moderate to severe HS (November 2024), and for active psoriatic arthritis, active non-radiographic axial spondyloarthritis and active ankylosing spondylitis (September 2024). In May 2025, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) will consider UCB’s application to PBS-list Bimzelx® for moderate to severe HS.